How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

LP

NASDAQ:LPTX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

LP

Leap Therapeutics IncNASDAQ LPTX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is LPTX undervalued compared to its fair value?

The fair value of LPTX stock is hidden USD. Relative to the market price of 2.07 USD Leap Therapeutics Inc is hidden.

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and curr...[More about valuation]

Leap Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.081 $B

Price:

2.07 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.508

FINANCIALS

Leap Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.015 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.014 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.083 B
0.072 B

Financial Position Analysis

Assets

0.083 B
Current Assets
0.082 B
Total non-current assets
0.0012 B

Total current liabilities
0.011 B
Total non-current liabilities

Cash Flow Statement

-0.01 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.01 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Leap Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is LPTX attractive for investment based on fundamental analysis?

LPTX stock rating is hidden. Leap Therapeutics is a hidden by Eyestock methodology.

Get LPTX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

LPTX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for LPTX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Leap Therapeutics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Leap Therapeutics Inc dividends

LPTX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About LPTX stock

About the company Leap Therapeutics Inc

Market cap $B

0.081

Dividend yield

Shares outstanding

99.0214 B

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company’s pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. The company also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.

LPTX profile

  • Ticker

    LPTX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    24 January 2017

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    36

  • City

    Cambridge

  • Address

    47 Thorndike St Ste B1-1

  • Cusip

    52187K101